This company is no longer active
Zosano Pharma Management
Management criteria checks 2/4
Key information
Steven Lo
Chief executive officer
US$2.0m
Total compensation
| CEO salary percentage | 26.22% |
| CEO tenure | 3.1yrs |
| CEO ownership | 0.06% |
| Management average tenure | 3.1yrs |
| Board average tenure | 3.1yrs |
Recent management updates
No updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$55m |
| Dec 31 2021 | US$2m | US$533k | -US$30m |
| Sep 30 2021 | n/a | n/a | -US$31m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$1m | US$526k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$34m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$875k | US$106k | -US$38m |
Compensation vs Market: Steven's total compensation ($USD2.03M) is above average for companies of similar size in the US market ($USD748.73K).
Compensation vs Earnings: Steven's compensation has increased whilst the company is unprofitable.
CEO
Steven Lo (55 yo)
Mr. Steven Lo has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive Officer since October 21, 2019 and has been its Senior Vice President of Oper...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP of Operations | 3.1yrs | US$2.03m | 0.055% $ 1.9 | |
| Chief Financial Officer | 2.8yrs | US$675.66k | 0.012% $ 0.4 | |
| Vice President of Technical Operations | 3.8yrs | no data | no data | |
| Secretary | no data | no data | no data |
Experienced Management: ZSAN.Q's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Senior VP of Operations | 3.1yrs | US$2.03m | 0.055% $ 1.9 | |
| Lead Independent Director | 5.1yrs | US$97.84k | 0.017% $ 0.6 | |
| Independent Director | 3.8yrs | US$96.98k | 0.0044% $ 0.1 | |
| Independent Director | 1.5yrs | US$89.00k | 0% $ 0 | |
| Independent Director | less than a year | US$46.92k | no data |
Experienced Board: ZSAN.Q's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/11/27 10:31 |
| End of Day Share Price | 2022/11/25 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zosano Pharma Corporation is covered by 7 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | BTIG |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |